Bacteriology of non-oncologic post-operative breast infections: A retrospective cross-sectional study to guide empiric antibiotic coverage.
Abstract
[BACKGROUND] Antibiotic prophylaxis for non-oncologic breast surgeries is not well described by procedure type. This study identified the underlying microbiological etiologies and antibiotic sensitivities of culture-positive infections from non-oncologic breast surgeries that were performed at a major medical center to guide specific empiric antibiotic coverage.
[METHODS] A retrospective cohort study was conducted at a tertiary hospital from November 2018 to January 2024. Patients aged ≥18 years who underwent non-oncologic breast surgery with culture-confirmed infections were included. Procedures analyzed included mastopexy, augmentation, reduction, gender-affirming surgery, and prophylactic mastectomies with and without reconstruction. Organism profiles from the procedures with >1 culture-positive infection were compared with their antibiogram to guide empiric treatment.
[RESULTS] Among the 3457 non-oncologic breast procedures, 37 resulted in culture-positive infections (1.07%). Infected patients were older (mean age 44 vs 37 years, p<0.05), but no significant differences in sex, body mass index, tobacco use, or comorbidities were noted. Infection rates were similar between prosthetic (1.04%) and non-prosthetic (1.08%) procedures (p=0.94) but were significantly higher in the risk-reducing mastectomy cohort (3.65% vs 0.92%, p<0.01). Organism profiles varied with the procedure. Organisms isolated from all procedures were sensitive to vancomycin. Empiric treatment recommendations included vancomycin plus ciprofloxacin, piperacillin-tazobactam, levofloxacin, or ceftazidime depending on the procedure type.
[CONCLUSIONS] Microbial etiologies of surgical site infections following non-oncologic breast surgery differed with the procedure. Procedure-specific empiric antibiotic regimens may improve infection management. Institutional and regional antibiotic susceptibility should be investigated to inform clinical guidelines on antibiotic use.
[METHODS] A retrospective cohort study was conducted at a tertiary hospital from November 2018 to January 2024. Patients aged ≥18 years who underwent non-oncologic breast surgery with culture-confirmed infections were included. Procedures analyzed included mastopexy, augmentation, reduction, gender-affirming surgery, and prophylactic mastectomies with and without reconstruction. Organism profiles from the procedures with >1 culture-positive infection were compared with their antibiogram to guide empiric treatment.
[RESULTS] Among the 3457 non-oncologic breast procedures, 37 resulted in culture-positive infections (1.07%). Infected patients were older (mean age 44 vs 37 years, p<0.05), but no significant differences in sex, body mass index, tobacco use, or comorbidities were noted. Infection rates were similar between prosthetic (1.04%) and non-prosthetic (1.08%) procedures (p=0.94) but were significantly higher in the risk-reducing mastectomy cohort (3.65% vs 0.92%, p<0.01). Organism profiles varied with the procedure. Organisms isolated from all procedures were sensitive to vancomycin. Empiric treatment recommendations included vancomycin plus ciprofloxacin, piperacillin-tazobactam, levofloxacin, or ceftazidime depending on the procedure type.
[CONCLUSIONS] Microbial etiologies of surgical site infections following non-oncologic breast surgery differed with the procedure. Procedure-specific empiric antibiotic regimens may improve infection management. Institutional and regional antibiotic susceptibility should be investigated to inform clinical guidelines on antibiotic use.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 해부 | breast
|
유방 | dict | 6 | |
| 합병증 | infection
|
감염 | dict | 3 | |
| 시술 | mastopexy
|
유방성형술 | dict | 1 | |
| 약물 | vancomycin
|
C0042313
vancomycin
|
scispacy | 1 | |
| 약물 | ciprofloxacin
|
C0008809
ciprofloxacin
|
scispacy | 1 | |
| 약물 | piperacillin-tazobactam
|
C0250480
piperacillin-tazobactam combination
|
scispacy | 1 | |
| 약물 | levofloxacin
|
C0282386
levofloxacin
|
scispacy | 1 | |
| 약물 | ceftazidime
|
C0007559
ceftazidime
|
scispacy | 1 | |
| 약물 | [BACKGROUND] Antibiotic
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS]
|
scispacy | 1 | ||
| 질환 | breast infections
|
C0392317
Breast infection
|
scispacy | 1 | |
| 질환 | infections
|
C0851162
Infections of musculoskeletal system
|
scispacy | 1 | |
| 기타 | Patients
|
scispacy | 1 | ||
| 기타 | tobacco
|
scispacy | 1 |
MeSH Terms
Humans; Retrospective Studies; Female; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Surgical Wound Infection; Cross-Sectional Studies; Middle Aged; Mastectomy; Microbial Sensitivity Tests; Mammaplasty; Breast
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- The impact of three-dimensional simulation and virtual reality technologies on surgical decision-making and postoperative satisfaction in aesthetic surgery: a preliminary study.
- Cutaneous fistula of the breast: A complication of cosmetic autologous fat transfer.
- Epidermal inclusion cyst after breast reduction mammoplasty.
- Penetrating globe injury following periocular hyaluronic acid filler injection: A case report.
- Clinical outcomes of synthetic absorbable mesh use in breast surgery: First case series in reconstruction and aesthetic mastopexy.